Takeda boosts sales of Lundbeck-developed drug in H1 2021

Takeda's reported revenue, including the sales of the antidepressant Trintellix/Brintellix, which Takeda and Lundbeck market in a collaboration in the US and Japan, grew by 12.8 percent in the first half of the fiscal year.

In the months spanning April to September, which make up the first half of the staggered fiscal year of 2021, Takeda's revenue has gone up by 12.8 percent compared to the prior Covid-19-affected year, it reports in a press release on Thursday.

The Japanese pharmaceutical company has just presented results in its second quarterly report, marking the halfway point in the fiscal year of 2021.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Rumored GN purchase unlikely but not impossible, say analysts

A low value assessment, a high structural value, and no dominant shareholders make GN Group a reasonable investment case for international private equity firms and industrial players. But just how likely is it? Analysts reveal their best bets for what a GN acquisition could look like.

New CFO wants to shake things up at WSA

A mere month into her new job, Marianne Wiinholt, WS Audiology’s fifth chief financial officer since the firm was established through a merger in 2019, is heralding great structural changes.

Further reading

Related articles

Latest news

See all jobs